Bristol-Myers Squibb Co. (BMY)
Bristol-Myers Squibb Co. is a global pharmaceutical company focused on discovering, developing, and delivering innovative medicines in areas such as oncology, immunology, cardiovascular, and neuroscience. Founded in 1858, it has a long history of advancing health through its diverse portfolio of prescription therapies.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| November 3, 2025 | $0.62 | 2025-10-03 | 2025-10-03 |
| August 1, 2025 | $0.62 | 2025-07-03 | 2025-07-03 |
| May 1, 2025 | $0.62 | 2025-04-04 | 2025-04-04 |
| February 3, 2025 | $0.62 | 2025-01-03 | 2025-01-03 |
| November 1, 2024 | $0.60 | 2024-10-04 | 2024-10-04 |
Dividends Summary
- Bristol-Myers Squibb Co. has issued 88 dividend payments over the past 21 years
- The most recent dividend was paid 18 days ago, on November 3, 2025
- The highest dividend payed out to investors during this period was $0.62 per share
- The average dividend paid during this period was $0.39 per share.
Company News
A comprehensive report analyzing 576 metabolic collaboration and licensing deals from 2019 to 2025, providing insights into deal terms, financial structures, and key industry trends across biopharma companies.
Bristol Myers Squibb and Johnson & Johnson discontinued the Phase 3 Librexia ACS trial for heart drug milvexian after an interim analysis showed unlikely efficacy, though other related trials will continue.
The article highlights four high-yielding dividend stocks trading at attractive valuations amid market uncertainty, focusing on packaging and pharmaceutical companies with strong dividend histories and low valuation metrics.
Replimune Group's stock surged after the FDA accepted its resubmitted Biologics License Application for RP1, an investigational drug targeting advanced melanoma when combined with Bristol Myers Squibb's Opdivo.
The healthcare sector has gained momentum recently, with investors rushing to buy beaten-down stocks. The performance of major healthcare ETFs like XLV, VHT, IYH, and FHLC will depend on the upcoming earnings releases of big names like Pfizer, Merck, Amgen, AbbVie, Bristol Myers Squibb, and Eli Lilly.
